MedPath

Induction of anesthesia with spontaneous breathing in children

Phase 1
Not yet recruiting
Conditions
ASA grade I,II,III
Registration Number
CTRI/2018/07/014773
Lead Sponsor
Government of gujarat
Brief Summary

Intubation without prior administration ofmuscle relaxants is a common practice in children. However, Succinylcholine may beconsidered as the golden standard for optimizing intubation conditions butpotential for complications like rhabdomylosis, hyperkalemia, massester spasm,malignant hyperthermia should not be used routinely. Rocuronium is a suitable alternativebut use of nondepolorizing musclerelaxant may be associated with undersirable sideeffects such as prolonged neuromuscular block due to immaturing ofneuromuscular junctionin peadiatric patient. So inhalationalaneasthetia with adjuvant is a better alternative to Succinylcholine forintubation in children. Propofol has beenreported to possess some characteristic that provide adequate condition forintubation. Considering these point study is designed.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
60
Inclusion Criteria
  • Patients age: 1-5 years ASA grade I,II,III Elective/Emergency surgery Gender.
  • Male/Female.
Exclusion Criteria

Age < 1 and > 5 ASA grade IV, V Parent’s refusal Uncompensated systemic disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate condition of endotracheal intubationfrom starting anesthesia to the 15mins after endotracheal intubation
Secondary Outcome Measures
NameTimeMethod
hemodynamic parameters, attempt for intubation, complicationsfrom start of anesthesia induction to the 15 minutes after completion of surgery

Trial Locations

Locations (1)

civil hospital, ahmedabad

🇮🇳

Ahmadabad, GUJARAT, India

civil hospital, ahmedabad
🇮🇳Ahmadabad, GUJARAT, India
Dr Smita R Engineer
Principal investigator
9825504948
seng_90@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.